Oxford Cancer Biomarkers

0 Abonné

Internationally renowned Professors David Kerr and Nick La Thangue started OCB from the laboratories of the University of Oxford in 2012. Their aim was to discover and develop biomarkers using screening platforms to advance personalised medicine within oncology, specifically colorectal cancer and its treatments. Since then, we have built a world class development team consisting of industry professionals, leading scientists and oncologists, retaining strong links to Oxford University. Together we have developed pioneering biomarker technology products that put each individual patient at the centre of cancer treatment.

oncology chemotherapy science cancer dna colorectal cancer colorectalcancer biomarkers medicine

Tout plus

Activité
À propos

Colorectal Cancer Biomarker Testing

il y a 5 ans • 75 Vues

ToxNav

il y a 5 ans • 55 Vues

An evaluation of the clinical utility of a panel of variants in DPYD and ENOSF1 for predicting common capecitabine related toxicities

il y a 5 ans • 85 Vues

Internationally renowned Professors David Kerr and Nick La Thangue started OCB from the laboratories of the University of Oxford in 2012. Their aim was to discover and develop biomarkers using screening platforms to advance personalised medicine within oncology, specifically colorectal cancer and its treatments. Since then, we have built a world class development team consisting of industry professionals, leading scientists and oncologists, retaining strong links to Oxford University. Together we have developed pioneering biomarker technology products that put each individual patient at the centre of cancer treatment.

oncology chemotherapy science cancer dna colorectal cancer colorectalcancer biomarkers medicine

Tout plus